praziquantel.txt

CLINICAL USE

Treatment of tapeworm Hymenolepis nana Schistosoma haematobium worms infections

DOSE IN NORMAL RENAL FUNCTION

Tapeworm: 5–10 mg/kg after a light breakfastHymenolepis nana: 25 mg/kg Schistosomiasis: 20 mg/kg repeated after 4–6 hoursS. japonicum : 60 mg/kg in 3 divided doses on 1 day

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :312.4

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :80

%Excreted unchanged in urine &nbsp &nbsp : 80% as metabolites

Volume of distribution (L/kg) &nbsp &nbsp &nbsp :No data

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :1–1.5 (metabolites 4 hours)/Slightly increased

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 &nbsp &nbsp : Dose as in normal renal function

10 to 20 &nbsp &nbsp : Dose as in normal renal function

<10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function Use lower dose with caution

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in GFR <10 mL/min

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in GFR <10 mL/min

HDF/high flux &nbsp :Unknown dialysability. Dose as in GFR <10 mL/min

CAV/VVHD &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugsCarbamazepine, phenytoin, chloroquine: reduce bioavailability of praziquantelCimetidine and albendazole: increases bioavailability

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

Available on a named patient basis from Merck (Cysticide)One study did not show any adverse effects in a haemodialysis patient

Tags: post-by-auto-php